0 Ratings
ID

22331

Description

A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in Treatment Phase. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Link

https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Keywords

Versions (1)
  1. 5/30/17 5/30/17 -
Uploaded on

May 30, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    English

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    1 forms  
    Concomitant Medication
    Description

    Concomitant Medication

    Alias
    UMLS CUI-1
    C2347852 (Concomitant Agent)
    Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
    Description

    Concomitant agent

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C2347852 (Concomitant Agent)
    Concomitant Medication Changes
    Description

    Concomitant Medication Changes

    Alias
    UMLS CUI-1
    C2347852 (Concomitant Agent)
    Drug name (Trade Name preferred)
    Description

    Drug name

    Data type

    text

    Alias
    UMLS CUI [1]
    C0013227 (Pharmaceutical Preparations)
    SNOMED
    763158003
    LOINC
    LP100609-9
    SINGLE Dose/ Unit (e.g. 500mg)
    Description

    Single dose/Unit

    Data type

    float

    Alias
    UMLS CUI [1,1]
    C2826257 (Prior Medication Usage)
    UMLS CUI [1,2]
    C1960417 (Single dose characteristic)
    SNOMED
    426146003
    Frequency of this Dose (e.g. BID PRN)
    Description

    Frequency

    Data type

    text

    Alias
    UMLS CUI [1]
    C3476109 (Medication frequency)
    LOINC
    LP149758-7
    Route
    Description

    Concomitant Medication Route of Administration

    Data type

    text

    Alias
    UMLS CUI [1]
    C2826730 (Concomitant Medication Route of Administration)
    Indication
    Description

    Indication

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C2347852 (Concomitant Agent)
    UMLS CUI [1,2]
    C3146298 (Indication)
    Start Date/Time
    Description

    Start Date Time

    Data type

    datetime

    Alias
    UMLS CUI [1]
    C2827019 (Substance Use Start Date Time)
    End Date/Time
    Description

    Stop Date

    Data type

    datetime

    Alias
    UMLS CUI [1,1]
    C0013227 (Pharmaceutical Preparations)
    SNOMED
    763158003
    LOINC
    LP100609-9
    UMLS CUI [1,2]
    C0806020 (End date)
    SNOMED
    454551000124105
    LOINC
    MTHU008302
    UMLS CUI [2,1]
    C0013227 (Pharmaceutical Preparations)
    SNOMED
    763158003
    LOINC
    LP100609-9
    UMLS CUI [2,2]
    C1522314 (End Time)
    SNOMED
    397898000
    Continuing at end of Study?
    Description

    Continuing at end of study

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1553904 (continuing therapy)
    Back to the top of the page

    Similar models

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    1 forms
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    Concomitant Medication
    C2347852 (UMLS CUI-1)
    Concomitant agent
    Item
    Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
    boolean
    C2347852 (UMLS CUI [1])
    Item Group
    Concomitant Medication Changes
    C2347852 (UMLS CUI-1)
    Drug name
    Item
    Drug name (Trade Name preferred)
    text
    C0013227 (UMLS CUI [1])
    Single dose/Unit
    Item
    SINGLE Dose/ Unit (e.g. 500mg)
    float
    C2826257 (UMLS CUI [1,1])
    C1960417 (UMLS CUI [1,2])
    Frequency
    Item
    Frequency of this Dose (e.g. BID PRN)
    text
    C3476109 (UMLS CUI [1])
    Concomitant Medication Route of Administration
    Item
    Route
    text
    C2826730 (UMLS CUI [1])
    Indication
    Item
    Indication
    text
    C2347852 (UMLS CUI [1,1])
    C3146298 (UMLS CUI [1,2])
    Start Date Time
    Item
    Start Date/Time
    datetime
    C2827019 (UMLS CUI [1])
    Stop Date
    Item
    End Date/Time
    datetime
    C0013227 (UMLS CUI [1,1])
    C0806020 (UMLS CUI [1,2])
    C0013227 (UMLS CUI [2,1])
    C1522314 (UMLS CUI [2,2])
    Continuing at end of study
    Item
    Continuing at end of Study?
    boolean
    C1553904 (UMLS CUI [1])
    Back to the top of the page 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial